Literature DB >> 22654917

Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease.

Yasufumi Masaki1, Nozomu Kurose, Motohisa Yamamoto, Hiroki Takahashi, Takako Saeki, Atsushi Azumi, Shinji Nakada, Shoko Matsui, Tomoki Origuchi, Susumu Nishiyama, Kazunori Yamada, Mitsuhiro Kawano, Akira Hirabayashi, Keita Fujikawa, Tomoko Sugiura, Masanobu Horikoshi, Naoto Umeda, Hiroshi Minato, Takuji Nakamura, Haruka Iwao, Akio Nakajima, Miyuki Miki, Tomoyuki Sakai, Toshioki Sawaki, Takafumi Kawanami, Yoshimasa Fujita, Masao Tanaka, Toshihiro Fukushima, Katumi Eguchi, Susumu Sugai, Hisanori Umehara.   

Abstract

IgG4-related disease is a new disease classification established in Japan in the 21st century. Patients with IgG4-related disease display hyper-IgG4-gammaglobulinemia, massive infiltration of IgG4+ plasma cells into tissue, and good response to glucocorticoids. Since IgG4 overexpression is also observed in other disorders, it is necessary to diagnose IgG4-related disease carefully and correctly. We therefore sought to determine cutoff values for serum IgG4 and IgG4/IgG and for IgG4+/IgG+ plasma cells in tissue diagnostic of IgG4-related disease. Patients and Methods. We retrospectively analyzed serum IgG4 concentrations and IgG4/IgG ratio and IgG4+/IgG+ plasma cell ratio in tissues of 132 patients with IgG4-related disease and 48 patients with other disorders. Result. Serum IgG4 >135  mg/dl demonstrated a sensitivity of 97.0% and a specificity of 79.6% in diagnosing IgG4-related disease, and serum IgG4/IgG ratios >8% had a sensitivity and specificity of 95.5% and 87.5%, respectively. IgG4+cell/IgG+ cell ratio in tissues >40% had a sensitivity and specificity of 94.4% and 85.7%, respectively. However, the number of IgG4+ cells was reduced in severely fibrotic parts of tissues. Conclusion. Although a recent unanimous consensus of all relevant researchers in Japan recently established the diagnostic criteria for IgG4-related disease, findings such as ours indicate that further discussion is needed.

Entities:  

Year:  2012        PMID: 22654917      PMCID: PMC3357966          DOI: 10.1155/2012/580814

Source DB:  PubMed          Journal:  Int J Rheumatol        ISSN: 1687-9260


1. Introduction

IgG4-related disease (IgG4-RD), a new disease classification first established in Japan in the 21st century, is characterized by hyper-IgG4-gammaglobulinemia and massive infiltration of IgG4-positive plasma cells into various swollen organs [1-10]. In general, a serum IgG4 concentration >135 mg/dL has been established as the cutoff value for the diagnosis of patients with IgG4-RD and is used in the joint consensus criteria of the Okazaki and Umehara groups investigating IgG4-RD for the Ministry of Health, Labor, and Welfare of Japan [11]. Some patients with early or limited stage IgG4-RD, however, may show the sufficient pathological characteristics and clinical features of this disease, such as good response to glucocorticoids, despite having serum IgG4 concentrations <135 mg/dL. In addition, an IgG4+/IgG+ ratio >40% in tissue and >10 cells/high-power field (HPF) have been used in the histopathologic diagnosis of IgG4-RD in Japan. Thus, a proper diagnosis of these patients may require the use of other criteria, including IgG4+/IgG plasma cell ratio. Since lower cutoff values may increase sensitivity while decreasing specificity, it is necessary to establish accurate cut off values for this ratio. To better establish the diagnostic criteria for IgG4-RD, we, the members of the IgG4+MOLPS/Mikulicz's disease research group in Japan, sought to determine the cutoff values for serum IgG4 and IgG4/IgG and for IgG4+/IgG+ plasma cells in tissue diagnostic of IgG4-RD using retrospectively collected data.

2. Materials and Methods

2.1. Measurement of Serum IgG4 Concentration

Serum IgG4 concentrations and IgG4/IgG ratio and the ratio of IgG4+/IgG+ plasma cells in tissue were determined in 132 patients with IgG4-RD and 48 patients with other disorders registered retrospectively in the IgG4+MOLPS/Mikulicz's disease research group (Table 1). The 48 patients with other disorders included 33 with Sjögren's syndrome, 3 with multicentric Castleman's disease (MCD), 3 with B-cell lymphoma, 2 with sarcoidosis, and 1 each with Kimura's disease, ulcerative colitis, autoimmune hepatitis, IgG-type monoclonal gammopathy of undetermined significance, progressive transformation of the germinal center, scleritis, and severe keratoconjunctivitis sicca. The study was approved by the review boards of Kanazawa Medical University and all other collaborating institutions, and all patients provided written informed consent for the use of their data and samples. The sensitivities, specificities, and ROC curves of serum IgG4 >135 mg/dL and various serum IgG4/IgG ratios were statistically analyzed using SPSS v.11 (SPSS Inc., Chicago, IL, USA).
Table 1

Involved organs in 132 patients with IgG4-RD. More than half (64 cases) the patients in our series had so-called Mikulicz's disease, with symmetrical swelling of at least two sets of lacrimal, parotid, or submandibular glands.

Involved organNumber of patients
Total132

Lacrimal gland75
Parotid gland32
Submandibular gland74
Pancreas20
Kidney21
Lung6
Lymph node4
Thyroid4
Liver3
Retroperitoneum3
Dura1
Hypophysis1
Bile duct1
Patients with borderline IgG4-RD were defined carefully as those with (1) >40% IgG4+/IgG+ plasma cells in tissue, (2) strict pathological differential, and (3) a typical clinical course (spontaneous regression or no change without treatment, or good response to an initial daily dose of <0.6 mg/kg prednisolone).

2.2. Analysis of IgG4+ Cells in Tissue

The numbers of IgG4+ and IgG+ cells in tissue samples from 36 patients with IgG4-RD and from 21 with other disorders were determined by counting cells counts in 5 high-power fields (HPF) under light microscopy. We also recounted cell areas of 17 samples from patients with IgG4-RD that contained both fibrotic and nonfibrotic parts. We also assessed the sensitivity and specificity of IgG4+/IgG+ cell ratios >10%, >20%, >30%, >40%, and >50%, and of >10, >20, >30, >40 and >50 IgG4+cells/HPF, as well as the presence of obliterative phlebitis, storiform fibrosis, eosinophilia, fibrosis, and lymphocyte infiltration as determined by hematoxylin and eosin staining in the diagnosis of IgG4-RD. Tissue samples with borderline IgG4-RD were defined as those with (1) serum IgG4 >135 mg/dL, (2) strict pathological differential, and (3) typical clinical course. Clinical course including response to steroid is not included in the comprehensive diagnostic criteria for IgG4-RD, to avoid the needless treatment with steroid of patients suspected of having IgG4-RD. As this was a retrospective analysis, however, we analyzed the clinical course of these borderline patients, including their response to steroid treatment.

3. Results

3.1. Serum IgG4 Concentration

A serum IgG4 cutoff value >135 mg/dL had a sensitivity of 97.0% and a specificity of 79.6% for the diagnosis of IgG4-RD. In 4 patients with relatively small and restricted lesions, however, this criterion was not adequate to diagnose IgG4-RD, although all had a histopathology and clinical course compatible with IgG4-RD (Table 2). All 4 patients were diagnosed with IgG4-RD based on a serum IgG4/IgG ratio >8%.
Table 2

Serum IgG and IgG4 concentrations and IgG4/IgG4 ratio of patients with false-positive and false-negative diagnoses of IgG4-RD.

False positives

DiagnosisIgG (mg/dL)IgG4 (mg/dL)IgG4/IgG

(1) MCD7,0804,56064.4%
(2) MCD4,42069015.6%
(3) B-cell lymphoma2,51045618.2%
(4) MCD2,96029510.0%
(5) MCD2,47629511.9%
(6) B-cell lymphoma4,0102716.8%
(7) Scleritis2,9002328.0%
(8) Sarcoidosis1,38018913.7%
(9) Sjögren's syndrome3,9201714.4%
(10) Malignant lymphoma1,9301417.3%

False negatives

DiagnosisIgG(mg/dL)IgG4(mg/dL)IgG4/IgG

(1) IgG4-RD1,14912510.9%
(2) IgG4-RD1,21012310.2%
(3) IgG4-RD1,2281119.0%
(4) IgG4-RD1,2601068.4%

IgG4-RD: IgG4-related disease; MCD: multicentric Castleman's disease.

In contrast, neither a serum IgG4 cutoff of >135 mg/dL nor a serum IgG4/IgG ratio >8% was adequate for the diagnosis of four patients with MCD and one each with B-cell lymphoma, scleritis, and Sjögren's syndrome, because all of these patients had hyper-IgG4-globulinemia associated with polyclonal gammopathy. We therefore estimated the sensitivity and specificity of various IgG4/IgG ratios (Table 3). We found that the ROC curves for absolute serum IgG4 concentration and serum IgG4/IgG ratio were almost identical (Figure 1).
Table 3

Sensitivity and specificity of serum cutoff values in the diagnosis of IgG4-RD.

SensitivitySpecificity
IgG4 > 135 mg/dL97.0%79.6%
IgG4/IgG > 5%99.2%83.3%
IgG4/IgG > 6%97.0%83.3%
IgG4/IgG > 7%97.0%85.4%
IgG4/IgG > 8%95.5%87.5%
IgG4/IgG > 9%92.4%89.6%
IgG4/IgG > 10%89.4%91.7%
Figure 1

ROC curves of absolute serum IgG4 concentration (green) and serum IgG4/IgG ratio (blue). The two curves were almost identical.

3.2. Analysis of IgG4+ Cells in Tissue Samples

We also assessed the ability of the ratio of IgG4+/IgG+ plasma cell ratios in 5 HPFs of tissue samples to diagnose IgG4-RD. We found that a ratio >40% had a sensitivity of 94.4% and a specificity of 85.7% (Table 4). Although >10 IgG4+ cells per HPF had a sensitivity of 100%, They had specificities of only 38.1%.
Table 4

Sensitivity and specificity of pathological findings for the diagnosis of IgG4-RD.

SensitivitySpecificity
IgG4+/IgG+ > 10%100.0%33.3%
IgG4+/IgG+ > 20%100.0%47.6%
IgG4+/IgG+ > 30%100.0%71.4%
IgG4+/IgG+ > 40%94.4%85.7%
IgG4+/IgG+ > 50%94.4%95.2%
IgG4+cells/HPF > 10100.0%38.1%
IgG4+cells/HPF > 2097.2%42.9%
IgG4+cells/HPF > 3097.2%61.9%
IgG4+cells/HPF > 4091.7%66.7%
IgG4+cells/HPF > 5086.1%71.4%
Obliterative phlebitis54.5%100.0%
Storiform fibrosis31.4%100.0%
Eosinophilia42.9%100.0%
Fibrosis91.4%82.4%
Lymphocytic infiltration100.0%16.7%
In tissues containing both fibrotic and nonfibrotic areas, we counting the number cells in each part showed that fibrotic areas contained fewer IgG4+ cells (Table 5).
Table 5

Recounting in each areas of 17 samples containing both fibrotic and nonfibrotic parts. All patients were diagnosed with IgG4-RD but had biopsy specimens that were too small (samples 1–14) or with relatively large fibrotic areas inadequate to diagnose IgG4-RD (samples 15–17). All samples had >10 IgG4+ cells per HPF.

TissueFibrosis+Fibrosis−
(1) Pancreas76.6%94.0%
(2) Submandibular gland75.4%89.2%
(3) Submandibular gland72.1%73.0%
(4) Submandibular gland72.1%97.3%
(5) Submandibular gland71.8%99.1%
(6) Pancreas67.7%95.0%
(7) Labial salivary glands65.0%70.8%
(8) Lung58.9%94.4%
(9) Submandibular gland49.2%68.9%
(10) Gall bladder48.6%94.0%
(11) Bile duct46.8%95.0%
(12) Submandibular gland46.2%74.1%
(13) Orbit44.2%94.4%
(14) Submandibular gland43.6%95.0%
(15) Submandibular gland33.3%95.0%
(16) Submandibular gland25.9%51.5%
(17) Labial salivary glands8.0%76.2%
We also assessed the ability of obliterative phlebitis and storiform fibrosis to diagnose IgG4-RD. Although both had specificities of 100%, their sensitivities were not very high (Table 4).

4. Discussion

Serum IgG4 >135 mg/dL has been widely accepted as a cutoff value for diagnosis of IgG4-RD. Although this concentration was determined by comparing patients with IgG4-related sclerosing pancreatitis and those with pancreatic cancer [1], it has also been used to diagnose IgG4-RD involving other organs. For example, we have utilized this cutoff value as a diagnostic criterion for IgG4-related Mikulicz's disease [5] and IgG4-related kidney disease [12], and, in 2011, it was adopted in the comprehensive clinical diagnostic criteria of IgG4-related diseases [11]. Most patients with IgG4-RD show multiple organ involvement at diagnosis, with both high absolute serum IgG4 concentrations and serum IgG4/IgG ratios. However, some patients with early and/or limited stage IgG4-RD do not present with high IgG4-globulinemia (Figure 2), with some not having IgG4 concentrations >135 mg/dL. We have therefore tested the ability of alternative criteria to diagnose for IgG4-RD. Although we found that a serum IgG4/IgG ratio >5% had the highest sensitivity, the normal ratio is about 5-6%, making this cut off value misleading. An IgG4/IgG ratio >8% had a sensitivity similar to that of absolute IgG4 >135 mg/dL, but a greater specificity, enabling us to diagnose 4 patients with lower absolute IgG4 concentrations as having IgG4-RD (Table 2). Since the standard cut off of absolute IgG4 >135 mg/dL demonstrated excellent sensitivity and specificity, it should be utilized, except for patients with early and/or limited IgG4-RD, for whom we propose using an IgG4/IgG ratio >8%.
Figure 2

Histopathology of a patient with limited stage IgG4-related dacryoadenitis. A 35-year-old woman presented with swelling of her bilateral lacrimal glands. Her serum IgG and IgG4 concentrations were 1,149 mg/dL and 125 mg/dL, respectively, and her serum IgG4/IgG ratio was 10.88%. Histopathological examination of a lacrimal gland biopsy revealed IgG4+ plasma cell infiltration, with an IgG4+/IgG+ cell ratio of 74.7%, and 53 IgG4+ cells per HPF, although sclerotic changes were not severe. Treatment with prednisolone 20 mg/day resulted in a rapid and dramatic improvement in symptoms. Although using an absolute serum IgG4 cutoff concentration of >135 mg did not result in diagnosis of IgG4-RD, her clinical course and histopathology were typical of IgG4-RD. However, using a serum IgG4/IgG ratio >8% as a cutoff value resulted in a diagnosis of IgG4-RD.

Careful diagnosis is required in patients with lower IgG4 concentrations, since those patients may have other distinct disorders with different clinical features than IgG4-RD. Patients with untypical clinical courses, including glucocorticoid refractoriness, should be reassessed. IgG4+/IgG+ plasma cell ratios in tissue >40% and >50%, and >10 IgG4+ cells per HPF have been used for the diagnosis of IgG4-RD. We found that an IgG4+/IgG+ cell ratio >40% in tissue had a sensitivity of 94.4% and a specificity of 85.7% in the diagnosis of IgG4-RD. We also found that IgG4+ plasma cell concentrations in tissue were diminished in fibrotic tissue areas, suggesting that a ratio >40% is a better histopathologic cutoff value. The presence of obliterative phlebitis and storiform fibrosis demonstrated specificities of 100%, but their sensitivities were much lower, indicating that these findings would be useful when added to, but not in place of, other results. Since patients with disorders such as MCD and lymphoma may demonstrate hyper-IgG4-gammaglobulinemia and massive IgG4+ plasma cell infiltration in tissue, serum IgG4 concentration and IgG4+ cells in tissue are not specific indicators of IgG4-RD. Rather, a diagnosis of IgG4-RD should be based on the overall balance of clinical features, such as disease distribution throughout the body, clinical course, serum concentrations, and histopathology. The pathologic consensus statement of the first international Symposium on IgG4-RD in Boston did not adopt IgG4+/IgG+ cell ratio in tissue as diagnostic, although it did suggest cutoffs for numbers of IgG4+ cells in HPFs of various organs. This, however, may be confusing for many pathologists and physicians. Although pathologic findings are very important in the diagnosis for IgG4-RD, clinical features and serological findings should be included. Recently, some patients with IgG4-RD were found to have lymphoma [13, 14] and other types of cancer [15, 16]. Thus IgG4-RD may not always be a benign disease with good prognosis. Many patients referred to our centers with glucocorticoid refractory IgG4-RD were diagnosed incorrectly, suggesting the need for more accurate diagnostic criteria for these diseases.
  15 in total

Review 1.  IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights.

Authors:  Yasufumi Masaki; Susumu Sugai; Hisanori Umehara
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

2.  Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis.

Authors:  Takako Saeki; Shinichi Nishi; Naofumi Imai; Tomoyuki Ito; Hajime Yamazaki; Mitsuhiro Kawano; Motohisa Yamamoto; Hiroki Takahashi; Shoko Matsui; Shinji Nakada; Tomoki Origuchi; Akira Hirabayashi; Noriyuki Homma; Yutaka Tsubata; Takuma Takata; Yoko Wada; Akihiko Saito; Sachiko Fukase; Kunihiro Ishioka; Kana Miyazaki; Yasufumi Masaki; Hisanori Umehara; Susumu Sugai; Ichiei Narita
Journal:  Kidney Int       Date:  2010-08-18       Impact factor: 10.612

3.  The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome--expansion of SIPS to the territory of Castleman's disease.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Kohhei Hasebe; Chisako Suzuki; Yasuyoshi Naishiro; Toshiaki Hayashi; Hiroyuki Yamamoto; Tadao Ishida; Yasuhisa Shinomura
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

4.  Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.

Authors:  Y Masaki; L Dong; N Kurose; K Kitagawa; Y Morikawa; M Yamamoto; H Takahashi; Y Shinomura; K Imai; T Saeki; A Azumi; S Nakada; E Sugiyama; S Matsui; T Origuchi; S Nishiyama; I Nishimori; T Nojima; K Yamada; M Kawano; Y Zen; M Kaneko; K Miyazaki; K Tsubota; K Eguchi; K Tomoda; T Sawaki; T Kawanami; M Tanaka; T Fukushima; S Sugai; H Umehara
Journal:  Ann Rheum Dis       Date:  2008-08-13       Impact factor: 19.103

5.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  Pancreatic cancer with a high serum IgG4 concentration.

Authors:  Terumi Kamisawa; Pong-Yui Chen; Yuyang Tu; Hitoshi Nakajima; Naoto Egawa; Kouji Tsuruta; Atsutake Okamoto; Tsunekazu Hishima
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Proposal for diagnostic criteria for IgG4-related kidney disease.

Authors:  Mitsuhiro Kawano; Takako Saeki; Hitoshi Nakashima; Shinichi Nishi; Yutaka Yamaguchi; Satoshi Hisano; Nobuaki Yamanaka; Dai Inoue; Motohisa Yamamoto; Hiroki Takahashi; Hideki Nomura; Takashi Taguchi; Hisanori Umehara; Hirofumi Makino; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2011-09-07       Impact factor: 2.801

Review 8.  Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Atsutake Okamoto
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

9.  Early bile duct cancer in a background of sclerosing cholangitis and autoimmune pancreatitis.

Authors:  Hyoung-Chul Oh; Jae Gyu Kim; Jeong Wook Kim; Kwang Sun Lee; Mi Kyung Kim; Kyong Choun Chi; Yong Seok Kim; Ki Hyun Kim
Journal:  Intern Med       Date:  2008-12-01       Impact factor: 1.271

10.  Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease.

Authors:  Wah Cheuk; Hunter K L Yuen; Alexander C L Chan; Lee-Yung Shih; Tseng-Tong Kuo; Ming-Wai Ma; Yan-Fai Lo; Wai-Kong Chan; John K C Chan
Journal:  Am J Surg Pathol       Date:  2008-08       Impact factor: 6.394

View more
  50 in total

1.  Immunoglobulin G4-related lung disease: a disease with many different faces.

Authors:  Phillip Hui; Andre Mattman; Pearce G Wilcox; Joanne L Wright; Don D Sin
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

2.  A Case of IgG4-Related Disease Presenting as Massive Pleural Effusion and Thrombophlebitis.

Authors:  Jong Hyun Choi; Jae Kyeom Sim; Jee Youn Oh; Eun Joo Lee; Gyu Young Hur; Seung Heon Lee; Sung Yong Lee; Je Hyeong Kim; Sang Yeub Lee; Chol Shin; Jae Jeong Shim; Kwang Ho In; Kyung Ho Kang; Kyung Hoon Min
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-04-25

Review 3.  [Hypophysitis : Types and differential diagnosis].

Authors:  W Saeger
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

4.  Immunoglobulin G4-related disease in a 66-year-old man with proptosis.

Authors:  Shannon M Ruzycki; Margaret M Kelly; Jay L Patel
Journal:  CMAJ       Date:  2016-06-20       Impact factor: 8.262

Review 5.  IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment.

Authors:  Alexander Kleger; Thomas Seufferlein; Martin Wagner; Andrea Tannapfel; Thomas K Hoffmann; Julia Mayerle
Journal:  Dtsch Arztebl Int       Date:  2015-02-20       Impact factor: 5.594

Review 6.  Diagnostic and treatment workup for IgG4-related disease.

Authors:  Mary Abraham; Arezou Khosroshahi
Journal:  Expert Rev Clin Immunol       Date:  2017-07-24       Impact factor: 4.473

7.  Lung Manifestations of IgG4-related Disease. A multifaceted disorder. Presentation of two cases and short review of the literature.

Authors:  Sara Ramponi; Letizia Gnetti; Maurizio Marvisi; Giuseppina Bertorelli; Alfredo Chetta
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

8.  The rare case report of interstitial lung disease with normal serum level of IgG4 developed six years after treatment of autoimmune pancreatitis.

Authors:  Tatjana Adzic-Vukicevic; Jelena Stojsic; Aleksandra Barac; Ana Blanka Protic; Sladjana Andrejevic; Snezana Raljevic
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

9.  Serum immunoglobulin G4 in Sjögren's syndrome: a pilot study.

Authors:  Maria Maślińska; Bożena Wojciechowska; Małgorzata Mańczak; Brygida Kwiatkowska
Journal:  Rheumatol Int       Date:  2020-02-15       Impact factor: 2.631

10.  IgG4 and IgE co-positive group found in idiopathic orbital inflammatory disease.

Authors:  Peng-Xiang Zhao; Yao Mawulikplimi Adzavon; Jian-Min Ma; Lei Shang; Dan-Ying Chen; Fei Xie; Meng-Yu Liu; Xin Zhang; Bao-Bei Lyu; Ming-Zi Zhang; Lin-Qi Yang; Xue-Mei Ma
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.